Naoyuki Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naoyuki Yamamoto has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Kazuhiko Miyanaga
School of Life Science and Technology Tokyo Institute of Technology Yokohama Kanagawa Japan
7 shared publicationsShun Iwatani
School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa 226-8501, Japan
5 shared publications- Zheng Lin Tan
ReMed Regenerative Medicine Clinical Application Institute
5 shared publications - Tadashi Ishida
Department of Mechanical Engineering, Institute of Science Tokyo, 4529 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
4 shared publications - Kazuhiko Miyanaga
Division of Bacteriology, Department of Infection and Immunity, School of Medicine, Jichi Medical University, Shimotsuke 329-0498, Japan
3 shared publications Moe Fukunaga
School of Life Science and Technology Tokyo Institute of Technology Yokohama Japan
3 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Elsevier in SSRN Electronic Journal
A potential sleep-modulating effect of A2 milk-derived casein hydrolysate containing opioid peptide CM-12: A randomized placebo-controlled crossover pilot trial
Milk‐derived bioactive peptides that influence sleep quality are emerging as promising functional food ingredients in today’s increasingly stressful society. Insufficient sleep is a growing health concern, for which food-derived bioactive peptides have emerged as potential modulators of sleep quality. CM-12, an A2 milk-derived opioid peptide produced using the Aspergillus oryzae protease Alp, has been shown to have anxiolytic activity in mice. We evaluated the effects of CM-12 casein hydrolysate in adults with poor sleep quality. Objective sleep parameters were assessed using a non-contact sleep mat, and subjective outcomes were evaluated using the OSA-MA and a questionnaire. Among 22 participants completing both intervention phases, CM-12 casein hydrolysate supplementation showed trends toward a shorter sleep-onset latency, greater sleep efficiency, and lower arousal, but no significant difference between CM-12 and placebo groups. However, stress‐stratified analysis revealed that participants experiencing lower treatment‐related stress showed significant increases in total sleep time with CM‐12. No adverse events or clinically relevant abnormalities were observed. These findings provide the first clinical evidence suggesting that CM-12 casein hydrolysate may contribute to sleep initiation and nocturnal stability, thus warranting confirmation in larger trials for commercial use.
- 12 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA potential sleep-modulating effect of A2 milk-derived casein hydrolysate containing opioid peptide CM-12: A randomized placebo-controlled crossover pilot trial
Milk‐derived bioactive peptides that influence sleep quality are emerging as promising functional food ingredients in today’s increasingly stressful society. Insufficient sleep is a growing health concern, for which food-derived bioactive peptides have emerged as potential modulators of sleep quality. CM-12, an A2 milk-derived opioid peptide produced using the Aspergillus oryzae protease Alp, has been shown to have anxiolytic activity in mice. We evaluated the effects of CM-12 casein hydrolysate in adults with poor sleep quality. Objective sleep parameters were assessed using a non-contact sleep mat, and subjective outcomes were evaluated using the OSA-MA and a questionnaire. Among 22 participants completing both intervention phases, CM-12 casein hydrolysate supplementation showed trends toward a shorter sleep-onset latency, greater sleep efficiency, and lower arousal, but no significant difference between CM-12 and placebo groups. However, stress‐stratified analysis revealed that participants experiencing lower treatment‐related stress showed significant increases in total sleep time with CM‐12. No adverse events or clinically relevant abnormalities were observed. These findings provide the first clinical evidence suggesting that CM-12 casein hydrolysate may contribute to sleep initiation and nocturnal stability, thus warranting confirmation in larger trials for commercial use.
- 1 March 2026
- Published by AIP Publishing in Biomicrofluidics
- Vol. 20 (2)
Microscopic analysis of angled particle transport in intestinal flow induced by moving textures on inner surfaces comparing native and pseudo–small intestines
The small intestine (SI) exhibits complex surface microstructures, such as villi and protrusions, which are believed to modulate local flow fields and promote the transport and absorption of luminal contents. However, the quantitative relationship between these surface morphologies and the microscopic flow dynamics remains poorly understood due to the intestine's intricate geometry and motion. To elucidate how intestinal microstructures shape near-wall flow fields and promote convective mixing, this study compares dynamic flows in a SI tube and a pseudo–small intestine (PSI) tube, serving as a simplified intestinal model, during contraction motion. The SI and PSI tubes are deformed using air-driven balloon actuators to mimic intestinal motion, and particle tracking experiments are performed to visualize the near-wall flow fields. The particle trajectories in the PSI show a uniform axially aligned motion, whereas those in the native SI exhibit substantial lateral displacement near the wall. Quantitative analysis reveals that lateral dispersion in the SI is approximately 14-fold higher than that in the PSI model, indicating that microscopic wall structures significantly enhance transverse transport. These findings suggest quantitative evidence on how intestinal microstructures shape microscopic flow fields and promote convective mixing.
- 1 March 2026
- Published by AIP Publishing in Biomicrofluidics
- Vol. 20 (2)
Microscopic analysis of angled particle transport in intestinal flow induced by moving textures on inner surfaces comparing native and pseudo–small intestines
The small intestine (SI) exhibits complex surface microstructures, such as villi and protrusions, which are believed to modulate local flow fields and promote the transport and absorption of luminal contents. However, the quantitative relationship between these surface morphologies and the microscopic flow dynamics remains poorly understood due to the intestine's intricate geometry and motion. To elucidate how intestinal microstructures shape near-wall flow fields and promote convective mixing, this study compares dynamic flows in a SI tube and a pseudo–small intestine (PSI) tube, serving as a simplified intestinal model, during contraction motion. The SI and PSI tubes are deformed using air-driven balloon actuators to mimic intestinal motion, and particle tracking experiments are performed to visualize the near-wall flow fields. The particle trajectories in the PSI show a uniform axially aligned motion, whereas those in the native SI exhibit substantial lateral displacement near the wall. Quantitative analysis reveals that lateral dispersion in the SI is approximately 14-fold higher than that in the PSI model, indicating that microscopic wall structures significantly enhance transverse transport. These findings suggest quantitative evidence on how intestinal microstructures shape microscopic flow fields and promote convective mixing.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
Development of biomimetic microfluidic device to study complex flow in small intestines by decoupling geometric determinants
A biomimetic microfluidic device independently controls intestinal wall geometry and motion. This reveals that villus-like structures enhance lateral particle spreading, while channel narrowing and wall actuation increase its magnitude.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
Development of biomimetic microfluidic device to study complex flow in small intestines by decoupling geometric determinants
A biomimetic microfluidic device independently controls intestinal wall geometry and motion. This reveals that villus-like structures enhance lateral particle spreading, while channel narrowing and wall actuation increase its magnitude.
- Open Access
Casomorphine-10 (CM-10) Peptide Orchestrates Circadian and Neurodevelopmental Gene Clusters via δ-Opioid Receptor Signaling: Insights from Transcriptome Analysis with δ-Opioid Receptor-Expressing HEK293 Cells
Background: β-casomorphin-10 (CM-10), a peptide fragment derived from milk casein with the sequence YPFPGPIPNS, has demonstrated notable anxiolytic activity in BALB/c mice. Yet, its cellular responses and mechanistic pathways remain largely uncharacterized. Methods: We performed RNA-seq analysis to profile gene expression changes in δ-opioid receptor-expressing HEK293 cells (DOR-HEK), comparing CM-10-treated and untreated conditions. Results: CM-10 exposure led to differential expression of 1714 genes in DOR-HEK cells, with 34 upregulated (>1.4-fold) (1.9%) and 1680 downregulated (p-value threshold of PRKAR2A, cAMP-responsive element-binding pathway, circadian rhythms, such as CLOCK, ARNT1, CRY2, PER1, and PER2, and anxiety and depression, such as NOTCH1, NOTCH2 and ANK2. A network with these selected genes was confirmed by STRING analysis. Conclusions: These findings indicate that CM-10 may activate DOR-mediated signaling by suppressing cAMP levels, implicating a distinct molecular cascade in HEK293 cells.
Open AccessCasomorphine-10 (CM-10) Peptide Orchestrates Circadian and Neurodevelopmental Gene Clusters via δ-Opioid Receptor Signaling: Insights from Transcriptome Analysis with δ-Opioid Receptor-Expressing HEK293 Cells
Background: β-casomorphin-10 (CM-10), a peptide fragment derived from milk casein with the sequence YPFPGPIPNS, has demonstrated notable anxiolytic activity in BALB/c mice. Yet, its cellular responses and mechanistic pathways remain largely uncharacterized. Methods: We performed RNA-seq analysis to profile gene expression changes in δ-opioid receptor-expressing HEK293 cells (DOR-HEK), comparing CM-10-treated and untreated conditions. Results: CM-10 exposure led to differential expression of 1714 genes in DOR-HEK cells, with 34 upregulated (>1.4-fold) (1.9%) and 1680 downregulated (p-value threshold of PRKAR2A, cAMP-responsive element-binding pathway, circadian rhythms, such as CLOCK, ARNT1, CRY2, PER1, and PER2, and anxiety and depression, such as NOTCH1, NOTCH2 and ANK2. A network with these selected genes was confirmed by STRING analysis. Conclusions: These findings indicate that CM-10 may activate DOR-mediated signaling by suppressing cAMP levels, implicating a distinct molecular cascade in HEK293 cells.
- Open Access
- 9 September 2024
- Published by Wiley in JSFA Reports
- Vol. 4 (9) , 336-347
Lactobacillus johnsonii colonizing in mice intestine contributes to control the gut barrier function via regeneration of the crypt in DSS‐treated mice
Background: Unbalanced gut microbiota is considered to cause dysfunction of the gut barrier function. Lactobacillus johnsonii MG, isolated from mouse feces as gut associating lactobacilli, enhanced gut barrier function in Caco‐2 cells via interaction with JAM‐2 in tight junctions. In this study, the anti‐inflammatory effects of L. johnsonii MG were investigated in a colitis mouse model developed by treating mice with 3% dextran sulfate sodium (DSS) for 9 days.Results: MG treatment of colitis mice resulted in fast recovery of the body weight and showed significant improvement in the disease activity index and histopathological scores. The histomorphological score increased by DSS treatment was significantly improved in the MG‐treated group. In the intestine, the expression of Ocln, Zo1, Itga6, Lama3, and Jam2 genes, which are involved in tight junction functions, were significantly upregulated in MG‐treated colitis mice. In the microflora analysis, the abundance of Ruminococcaceae, Bacteroides, and Lachnospiraceae were reduced in DSS‐treated mice and recovered by MG treatment.Conclusion: We reported the potential of L. johnsonii MG in the regeneration of crypts and integrity of matrix proteins in the gut of mice with colitis through its association with tight junctions. The experimental results provide new insights into the probiotic effect of tight junction associating L. johnsonii MG.
- 9 September 2024
- Published by Wiley in JSFA Reports
- Vol. 4 (9) , 336-347
Open AccessLactobacillus johnsonii colonizing in mice intestine contributes to control the gut barrier function via regeneration of the crypt in DSS‐treated mice
Background: Unbalanced gut microbiota is considered to cause dysfunction of the gut barrier function. Lactobacillus johnsonii MG, isolated from mouse feces as gut associating lactobacilli, enhanced gut barrier function in Caco‐2 cells via interaction with JAM‐2 in tight junctions. In this study, the anti‐inflammatory effects of L. johnsonii MG were investigated in a colitis mouse model developed by treating mice with 3% dextran sulfate sodium (DSS) for 9 days.Results: MG treatment of colitis mice resulted in fast recovery of the body weight and showed significant improvement in the disease activity index and histopathological scores. The histomorphological score increased by DSS treatment was significantly improved in the MG‐treated group. In the intestine, the expression of Ocln, Zo1, Itga6, Lama3, and Jam2 genes, which are involved in tight junction functions, were significantly upregulated in MG‐treated colitis mice. In the microflora analysis, the abundance of Ruminococcaceae, Bacteroides, and Lachnospiraceae were reduced in DSS‐treated mice and recovered by MG treatment.Conclusion: We reported the potential of L. johnsonii MG in the regeneration of crypts and integrity of matrix proteins in the gut of mice with colitis through its association with tight junctions. The experimental results provide new insights into the probiotic effect of tight junction associating L. johnsonii MG.
- 11 July 2024
- Published by Wiley in Journal of the Science of Food and Agriculture
- Vol. 104 (15) , 9210-9219
Release of CM‐12 from A2‐type casein by the cleavage of Ser–Leu–Xaa at the C‐terminus using Aspergillus oryzae alkaline protease
BACKGROUND: Aspergillus oryzae protease can release the opioid peptide β‐casomorphin‐10 (CM‐10, YPFPGPIPNS, 60–69) from A2‐type casein. However, not only is the yield of the active peptide low, but the key enzyme involved in processing has yet to be identified.RESULTS: A significant amount of the opioid peptide 60YPFPGPIPNSLP71 (CM‐12) was produced from the A2‐type casein peptide 53AQTQSLVYPFPGPIPNSLPQNIPPLTQTPV82 when the active protease in A. oryzae protease extract was fractionated with DEAE‐Sepharose. The fractionated enzyme produced CM‐12 from bovine A2‐type casein but not from bovine A1 casein. A major protein of 34 kDa was purified and identified as an alkaline protease (Alp). Motif prediction of the Alp cleavage site using Multiple EM for Motif Elicitation analysis revealed preferable cleavage at the C‐terminal end of Ser–Leu–Xaa for the release of CM‐12. A2‐type casein hydrolysate by Alp exhibited similar levels of opioid activity to that of synthetic CM‐12 in cAMP‐Glo assays with μ‐opioid receptor‐expressing HEK293 cells. These results suggest that CM‐12 is a major opioid peptide in the casein hydrolysate.CONCLUSION: Our findings showed that Alp fractionated from A. oryzae protease extract produced the opioid peptide CM‐12 from A2‐type casein as a result of preferential cleavage at the C‐terminal end of Ser–Leu–Xaa and the removal of coexisting enzymes. Moreover, docking predictions suggested a stable interaction between CM‐12 and the 3D structure of Alp. Casein hydrolysate with Alp‐containing CM‐12 has the potential for use as a bioactive peptide material with opioid activity. © 2024 Society of Chemical Industry.
- 11 July 2024
- Published by Wiley in Journal of the Science of Food and Agriculture
- Vol. 104 (15) , 9210-9219
Release of CM‐12 from A2‐type casein by the cleavage of Ser–Leu–Xaa at the C‐terminus using Aspergillus oryzae alkaline protease
BACKGROUND: Aspergillus oryzae protease can release the opioid peptide β‐casomorphin‐10 (CM‐10, YPFPGPIPNS, 60–69) from A2‐type casein. However, not only is the yield of the active peptide low, but the key enzyme involved in processing has yet to be identified.RESULTS: A significant amount of the opioid peptide 60YPFPGPIPNSLP71 (CM‐12) was produced from the A2‐type casein peptide 53AQTQSLVYPFPGPIPNSLPQNIPPLTQTPV82 when the active protease in A. oryzae protease extract was fractionated with DEAE‐Sepharose. The fractionated enzyme produced CM‐12 from bovine A2‐type casein but not from bovine A1 casein. A major protein of 34 kDa was purified and identified as an alkaline protease (Alp). Motif prediction of the Alp cleavage site using Multiple EM for Motif Elicitation analysis revealed preferable cleavage at the C‐terminal end of Ser–Leu–Xaa for the release of CM‐12. A2‐type casein hydrolysate by Alp exhibited similar levels of opioid activity to that of synthetic CM‐12 in cAMP‐Glo assays with μ‐opioid receptor‐expressing HEK293 cells. These results suggest that CM‐12 is a major opioid peptide in the casein hydrolysate.CONCLUSION: Our findings showed that Alp fractionated from A. oryzae protease extract produced the opioid peptide CM‐12 from A2‐type casein as a result of preferential cleavage at the C‐terminal end of Ser–Leu–Xaa and the removal of coexisting enzymes. Moreover, docking predictions suggested a stable interaction between CM‐12 and the 3D structure of Alp. Casein hydrolysate with Alp‐containing CM‐12 has the potential for use as a bioactive peptide material with opioid activity. © 2024 Society of Chemical Industry.
- Open Access
- 13 October 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (42) , 39662-39672
Exploration of DPP-IV Inhibitory Peptide Design Rules Assisted by the Deep Learning Pipeline That Identifies the Restriction Enzyme Cutting Site
The mining of antidiabetic dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (DPP-IV-IPs) is currently a costly and laborious process. Due to the absence of rational peptide design rules, it relies on cumbersome screening of unknown enzyme hydrolysates. Here, we present an enhanced deep learning model called bidirectional encoder representation (BERT)-DPPIV, specifically designed to classify DPP-IV-IPs and explore their design rules to discover potent candidates. The end-to-end model utilizes a fine-tuned BERT architecture to extract structural/functional information from input peptides and accurately identify DPP-IV-Ips from input peptides. Experimental results in the benchmark data set showed BERT-DPPIV yielded state-of-the-art accuracy and MCC of 0.894 and 0.790, surpassing the 0.797 and 0.594 obtained by the sequence-feature model. Furthermore, we leveraged the attention mechanism to uncover that our model could recognize the restriction enzyme cutting site and specific residues that contribute to the inhibition of DPP-IV. Moreover, guided by BERT-DPPIV, proposed design rules for DPP-IV inhibitory tripeptides and pentapeptides were validated, and they can be used to screen potent DPP-IV-IPs.
- 13 October 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (42) , 39662-39672
Open AccessExploration of DPP-IV Inhibitory Peptide Design Rules Assisted by the Deep Learning Pipeline That Identifies the Restriction Enzyme Cutting Site
The mining of antidiabetic dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (DPP-IV-IPs) is currently a costly and laborious process. Due to the absence of rational peptide design rules, it relies on cumbersome screening of unknown enzyme hydrolysates. Here, we present an enhanced deep learning model called bidirectional encoder representation (BERT)-DPPIV, specifically designed to classify DPP-IV-IPs and explore their design rules to discover potent candidates. The end-to-end model utilizes a fine-tuned BERT architecture to extract structural/functional information from input peptides and accurately identify DPP-IV-Ips from input peptides. Experimental results in the benchmark data set showed BERT-DPPIV yielded state-of-the-art accuracy and MCC of 0.894 and 0.790, surpassing the 0.797 and 0.594 obtained by the sequence-feature model. Furthermore, we leveraged the attention mechanism to uncover that our model could recognize the restriction enzyme cutting site and specific residues that contribute to the inhibition of DPP-IV. Moreover, guided by BERT-DPPIV, proposed design rules for DPP-IV inhibitory tripeptides and pentapeptides were validated, and they can be used to screen potent DPP-IV-IPs.
- 13 September 2023
- Published by Oxford University Press (OUP) in Bioscience, Biotechnology, and Biochemistry
- Vol. 87 (12) , 1532-1536
Enhanced tight junction in Caco-2 cells by the pretreatment with Lactobacillus johnsonii strain MG
We investigated roles of Lactobacillus johnsonii MG isolated from mice with interaction with tight junction on gut barrier function with Caco-2 cell model. Pretreatment with MG enhanced barrier function and showed protective effect against Enterococcus faecium provided damage. MG treatment increased the gene expressions of transcriptional regulator NFKB and major tight junction protein, ZO-1.
- 13 September 2023
- Published by Oxford University Press (OUP) in Bioscience, Biotechnology, and Biochemistry
- Vol. 87 (12) , 1532-1536
Enhanced tight junction in Caco-2 cells by the pretreatment with Lactobacillus johnsonii strain MG
We investigated roles of Lactobacillus johnsonii MG isolated from mice with interaction with tight junction on gut barrier function with Caco-2 cell model. Pretreatment with MG enhanced barrier function and showed protective effect against Enterococcus faecium provided damage. MG treatment increased the gene expressions of transcriptional regulator NFKB and major tight junction protein, ZO-1.
- Open Access
- 25 May 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (6) , 1393
GAPDH Released from Lactobacillus johnsonii MG Enhances Barrier Function by Upregulating Genes Associated with Tight Junctions
Extracellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has multiple interactions with various gut epithelial components. For instance, GAPDH in Lactobacillus johnsonii MG cells interacts with junctional adhesion molecule-2 (JAM-2) in Caco-2 cells and enhances tight junctions. However, the specificity of GAPDH toward JAM-2 and its role in the tight junctions in Caco-2 cells remain unclear. In the present study, we assessed the effect of GAPDH on tight junction regeneration and explored the GAPDH peptide fragments required for interaction with JAM-2. GAPDH was specifically bound to JAM-2 and rescued H2O2-damaged tight junctions in Caco-2 cells, with various genes being upregulated in the tight junctions. To understand the specific amino acid sequence of GAPDH that interacts with JAM-2, peptides interacting with JAM-2 and L. johnsonii MG cells were purified using HPLC and predicted using TOF–MS analysis. Two peptides, namely 11GRIGRLAF18 at the N-terminus and 323SFTCQMVRTLLKFATL338 at the C-terminus, displayed good interactions and docking with JAM-2. In contrast, the long peptide 52DSTHGTFNHEVSATDDSIVVDGKKYRVYAEPQAQNIPW89 was predicted to bind to the bacterial cell surface. Overall, we revealed a novel role of GAPDH purified from L. johnsonii MG in promoting the regeneration of damaged tight junctions and identified the specific sequences of GAPDH involved in JAM-2 binding and MG cell interaction.
- 25 May 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (6) , 1393
Open AccessGAPDH Released from Lactobacillus johnsonii MG Enhances Barrier Function by Upregulating Genes Associated with Tight Junctions
Extracellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has multiple interactions with various gut epithelial components. For instance, GAPDH in Lactobacillus johnsonii MG cells interacts with junctional adhesion molecule-2 (JAM-2) in Caco-2 cells and enhances tight junctions. However, the specificity of GAPDH toward JAM-2 and its role in the tight junctions in Caco-2 cells remain unclear. In the present study, we assessed the effect of GAPDH on tight junction regeneration and explored the GAPDH peptide fragments required for interaction with JAM-2. GAPDH was specifically bound to JAM-2 and rescued H2O2-damaged tight junctions in Caco-2 cells, with various genes being upregulated in the tight junctions. To understand the specific amino acid sequence of GAPDH that interacts with JAM-2, peptides interacting with JAM-2 and L. johnsonii MG cells were purified using HPLC and predicted using TOF–MS analysis. Two peptides, namely 11GRIGRLAF18 at the N-terminus and 323SFTCQMVRTLLKFATL338 at the C-terminus, displayed good interactions and docking with JAM-2. In contrast, the long peptide 52DSTHGTFNHEVSATDDSIVVDGKKYRVYAEPQAQNIPW89 was predicted to bind to the bacterial cell surface. Overall, we revealed a novel role of GAPDH purified from L. johnsonii MG in promoting the regeneration of damaged tight junctions and identified the specific sequences of GAPDH involved in JAM-2 binding and MG cell interaction.